Notice of Proposed Sale · 144
Avalo Therapeutics, Inc.
AVTXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- AVALO THERAPEUTICS, INC.
- Issuer CIK
- 0001534120
- SEC file number
- 001-37590
- Phone
- 410-522-8707
- Person for whose account securities are to be sold
- JENNIFER RILEY
- Relationships to issuer
- Officer
- Street
- 1500 LIBERTY RIDGE DRIVE
- Street (continued)
- SUITE 321
- City
- WAYNE
- State / country code
- PA
- Postal code
- 19087
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,655 | 52,012.25 | 53,630,000 | 08/11/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 12/10/2025 | Shares Purchased Through Employee Stock Purchase Plan | Issuer | 2,655 | N | 12/10/2025 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/11/2026
- Signed
- /s/ Jennifer Riley
Company context
Current securities
Recent company filings
- 144 filingAug 17, 2026
- SCHEDULE 13G/A - filed by Caligan Partners LP regarding Avalo Therapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G/A - filed by T. Rowe Price Investment Management, Inc. regarding Avalo Therapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G/A - filed by Avoro Capital Advisors LLC regarding Avalo Therapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Avalo Therapeutics, Inc.Aug 14, 2026